Evolus is a global performance beauty company delivering breakthrough products in the cash‑pay aesthetic market, with an expanding and increasingly diversified international footprint. Our portfolio includes Jeuveau^®, a proprietary neurotoxin with 14% U.S. market share and growing, and Evolysse^™, our next‑generation injectable hyaluronic acid gel collection designed by Symatese using innovative Cold‑X^™ technology. With commercialization across multiple international markets and continued geographic expansion, Evolus leverages its global platform while operating exclusively in the self‑pay segment, enabling a differentiated, customer‑centric model that supports licensed aesthetic practitioners through innovation, brand‑led growth, and practice‑enhancing programs. With a growing customer base and scalable global infrastructure, Evolus is well-positioned to drive durable growth and long-term value creation.

Learn More